Keywords
Rituximab treatment
Idiopathic membranous nephropathy
Submitted : 2024-02-18
Accepted : 2024-03-04
Published : 2024-03-19
Abstract
Objective: To investigate the efficacy of rituximab in the treatment of idiopathic membranous nephropathy with varying levels of serum phospholipase A2 receptor antibodies. Methods: A total of 137 patients with idiopathic membranous nephropathy admitted to Beijing Sixth Hospital were selected. Based on their blood PLA2R antibody levels before rituximab treatment, patients were categorized into the PLA2R antibody positive group (n = 94) and the PLA2R antibody negative group (n = 43). They were followed up for at least 1 year, during which the efficacy, measured through 24-hour urine protein quantification and serum albumin levels, were compared between the two groups before and after treatment. Results: After 3 months of treatment, there was no significant difference in the quantitative levels of 24-hour urine protein between the two groups (P > 0.05). However, after 6 and 12 months of treatment, there was a significant difference in the levels of 24-hour urine protein between the two groups (P < 0.05). Additionally, after 3 months of treatment, there was a notable difference in the serum albumin levels between the two groups (P < 0.05). However, after 6 and 12 months of treatment, there was no significant difference in serum albumin levels between the two groups (P > 0.05). Analysis of complications in the two groups revealed that in the positive group, 9 individuals experienced thrombosis, 5 had infections, and 11 developed acute kidney injury (AKI). In contrast, in the negative group, 5 individuals had thrombosis, 2 had infections, and 3 developed AKI. There was no statistically significant difference in complications between the two groups (P > 0.05). Conclusion: Serum anti-PLA2R antibody levels provide valuable insights into the clinical observation of rituximab treatment for idiopathic membranous nephropathy. They aid in understanding the disease’s pathogenesis, evaluating treatment efficacy, and predicting disease prognosis.
References
Li Z, Chen R, Lin Y, et al., 2023, Diagnostic Value of Serum Anti-PLA2R Antibodies for Idiopathic Membranous Nephropathy. Laboratory Medicine and Clinic, 20(21): 3183–3186.
Hao S, Ding X, Liu H, et al., 2023, Analysis of the Clinical Efficacy of a Single Low-Dose Rituximab in Treating Idiopathic Membranous Nephropathy. Journal of Clinical Nephrology, 23(9): 712–720.
Fang S, Wang Y, Ding Y, 2023, Application of B Cell Level Monitoring in Treating Idiopathic Membranous Nephropathy with a Single Dose of Rituximab. Zhongnan Pharmacy, 21(9): 2508–2510.
Shi Z, Li J, 2023, Research Progress in Traditional Chinese Medicine for Idiopathic Membranous Nephropathy. Chinese Modern Distance Education of Traditional Chinese Medicine, 21(18): 202–205.
Zhou L, Xu E, Wang Z, et al., 2023, Clinical Value of Serum Anti-PLA2R Antibodies and Glomerular PLA2R Antigen in Idiopathic Membranous Nephropathy. Journal of Medical Research, 52(9): 178–182.
Qiao L, Yang C, 2023, Urinary Immunoglobulin G4 and Interleukin-17 Levels and Clinical Significance in Patients with Idiopathic Membranous Nephropathy. Clinical Medical Engineering, 30(9): 1247–1248.
Li Z, Yang Z, 2023, Clinical Characteristics of Idiopathic Membranous Nephropathy Combined with Crescent Formation. Medical Theory and Practice, 36(17): 2954–2957.
Li Q, Zhang Q, Feng W, et al., 2023, Analysis of the Value of Dynamic Monitoring of Serum PLA2R Antibodies in the Diagnosis and Efficacy Evaluation of Idiopathic Membranous Nephropathy. Chinese Practical Medicine, 18(17): 95–98.
Li A, Liang L, Xu D, 2023, Research Progress on the Mechanism of Idiopathic Membranous Nephropathy Combined with Venous Thromboembolism. Journal of Shandong First Medical University (Shandong Academy of Medical Sciences), 44(8): 603–607.
Liu H, 2023, Clinical Observation on Treating Idiopathic Membranous Nephropathy with Mushen Prescription and Immunosuppression. Journal of Practical Traditional Chinese Medicine, 39(8): 1562–1563.
Zhang J, Wang R, Wang Y, et al., 2023, Clinical Analysis of Changes in Peripheral Blood Lymphocyte Subpopulations in Idiopathic Membranous Nephropathy with Different Prognosis and Efficacy. Chinese Journal of Integrated Traditional Chinese and Western Medicine Nephrology, 24(8): 683–687.
Gao H, Peng H, Liu F, et al., 2023, Based on Network Pharmacology to Explore the Mechanism of Phylloxera in Treating Idiopathic Membranous Nephropathy. Chinese Journal of Integrated Traditional Chinese and Western Medicine Nephrology, 24(8): 710–713 + 756.
Liu Z, Liang W, Ding G, 2023, Analysis of the Efficacy of Preventive Anticoagulation Therapy in Idiopathic Membranous Nephropathy. Journal of Medical Research, 52(8): 39–44 + 54.
Xu L, 2023, Clinical Effect of Low-Dose Tacrolimus Combined with Prednisone in Treating Idiopathic Membranous Nephropathy. Journal of Chronic Diseases, 24(8): 1228–1231.
Yuan L, Chen T, Fu Y, et al., 2022, The Role of Anti-PLA2R Antibodies in the Thrombotic Susceptibility State of Idiopathic Membranous Nephropathy. Chinese Journal of Gerontology, 2022, 42(21): 5270-5273.
Li Q, 2022, Expression Profile Analysis of Urinary Exosomes circRNAs in Idiopathic Membranous Nephropathy and Preliminary Study on the Diagnostic Potential and Mechanism of hsa_circ_0001250, thesis, Jilin University.
Liu Y, 2022, Clinical Effect of Rituximab in Treating Idiopathic Membranous Nephropathy. Clinical Medical Research and Practice, 7(31): 56–58.
Cui C, Gao P, Xu P, et al., 2022, Evaluation of the Clinical Application of PLA2R and THSD7A in Idiopathic Membranous Nephropathy. Journal of Bengbu Medical College, 47(9): 1167–1171.
Zhao C, Liu X, Guo Y, et al., 2022, Effect of Modified Buyang Huanwu Decoction Combined with Tacrolimus in the Treatment of Idiopathic Membranous Nephropathy of Qi Deficiency and Blood Stasis Type and Its Impact on Coagulation and Fibrinolysis Function, PLA2R and THSD7A Levels. Clinical Medical Research and Practice, 7(26): 114–117.
Guo J, Li J, Wang X, et al., 2022, The Effect of Spleen-Strengthening and Dampness-Removing Method Combined with Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy (Qi Deficiency, Blood Stasis, and Dampness Syndrome) and Its Regulatory Effect on CysC and Anti-PLA2R Levels. Chinese Medical Innovation, 19(25): 85–89.